Bristol-Myers Squibb's novel anticoagulant Eliquis (apixaban 2.5mg tablet) has been approved in Japan for the prevention of ischemic stroke and systemic embolism in patients with non-valvular atrial fibrillation, setting the stage for a market showdown with Bayer's Xarelto (rivaroxaban) and Boehringer Ingelheim's Prazaxa (dabigatran) in this setting.
The Japanese regulatory clearance for the BMS oral direct Factor Xa inhibitor comes hot on the heels of the EU...